SCHEMBL7055115

SCHEMBL7055115

CC(C)(C)[Si](C)(C)ONC(=O)[C@H](NS(=O)(=O)Cc1ccc2sccc2c1)c1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.36
BACE1 P56817 1/20 0.33
POLB P06746 1/20 0.33
MRGPRX4 Q96LA9 1/20 0.33
CTNNB1 P35222 1/20 0.33
WNT3A P56704 1/20 0.33
CYP2A6 P11509 1/20 0.33
ADRB3 P13945 1/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
MAPT P10636 2/20 0.33
ALDH1A1 P00352 2/20 0.33
LMNA P02545 1/20 0.33
GAA P10253 1/20 0.33
TSHR P16473 1/20 0.31
HSD17B10 Q99714 1/20 0.31
HTR2C P28335 1/20 0.31
SLC1A3 P43003 1/20 0.31
SLC1A2 P43004 1/20 0.31
SLC1A1 P43005 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7055123 1.00 TP53 (0.36) TP53BACE1POLBMRGPRX4CTNNB1
SCHEMBL7117234 0.83 CTNNB1 (0.36) TP53MRGPRX4CTNNB1WNT3ACYP2A6
SCHEMBL6738949 0.82 MEP1B (0.41) TP53BACE1MRGPRX4CTNNB1WNT3A
SCHEMBL6738953 0.82 MEP1B (0.41) TP53BACE1MRGPRX4CTNNB1WNT3A
SCHEMBL7127966 0.81 ATM (0.35) TP53MRGPRX4CTNNB1WNT3ACYP2A6
SCHEMBL6741909 0.81 CTNNB1 (0.41) TP53BACE1MRGPRX4CTNNB1WNT3A
SCHEMBL6734434 0.75 LY96 (0.35) MRGPRX4CYP2A6ADRB3
SCHEMBL6740820 0.75 MMP13 (0.43) CYP2A6ADRB3MEN1KMT2AMAPT
SCHEMBL6740817 0.75 MMP13 (0.43) CYP2A6ADRB3MEN1KMT2AMAPT
SCHEMBL7055114 0.74 PER2 (0.38) CTNNB1WNT3AADRB3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030199571-A1 (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives SMITHKLINE BEECHAM P.L.C. (GB) 2003-10-23 US disclosed
EP-1244616-A1 (HETERO)BICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES SmithKline Beecham plc (GB) 2002-10-02 EP disclosed
WO-2001047874-A1 (HETERO)BICYCLYMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES SMITHKLINE BEECHAM P.L.C. (GB) 2001-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199571-A1 (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives CD40, CD22, CD2 TP53 1628/4885BACE1 1597/4885POLB 3434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.